Cargando…

Influence of Luseogliflozin on Vaginal Bacterial and Fungal Populations in Japanese Patients With Type 2 Diabetes

BACKGROUND: Selective sodium-glucose cotransporter 2 inhibitors, known to lower the blood glucose levels by promoting the urinary glucose excretion, can predispose to genitourinary infections. This prospective study investigated the influence of selective sodium-glucose cotransporter 2 inhibitors lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kusunoki, Masataka, Tsutsumi, Kazuhiko, Wakazono, Naomi, Hisano, Fumiya, Miyata, Tetsuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166290/ https://www.ncbi.nlm.nih.gov/pubmed/34104283 http://dx.doi.org/10.14740/jocmr4504

Ejemplares similares

Effect of Treatment With Sodium-Glucose Cotransporter 2 Inhibitor on the Initiation of Continuous Positive Airway Pressure Therapy in Type 2 Diabetic Patients With Obstructive Sleep Apnea Syndrome
por: Kusunoki, Masataka, et al.
Publicado: (2021)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
por: Samukawa, Yoshishige, et al.
Publicado: (2018)

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
por: Ejiri, Kentaro, et al.
Publicado: (2020)

Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats
por: Xie, Keyu, et al.
Publicado: (2023)

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2014)

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Evaluation of potential activity of luseogliflozin on vascular proliferation in the mesenteric lymph node with or without vascular tumors in Sprague-Dawley rats in a carcinogenicity study
por: Sasaki, Minoru, et al.
Publicado: (2016)

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
por: Qiang, Shirong, et al.
Publicado: (2015)

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure
por: Ejiri, Kentaro, et al.
Publicado: (2022)

Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021)

Prevalence of posterior staphyloma and factors associated with its shape in the Japanese population
por: Numa, Shogo, et al.
Publicado: (2018)

Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
por: Sasaki, Takashi, et al.
Publicado: (2015)

Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus
por: Chino, Yukihiro, et al.
Publicado: (2021)

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet
por: Lee, Gendai
Publicado: (2022)

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2016)

Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
por: Furukawa, Shinya, et al.
Publicado: (2022)

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
por: Yamauchi, Yuki, et al.
Publicado: (2022)

A Comparative Study on the Efficacy and Safety of Dose Escalation of Luseogliflozin in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control
por: Arao, Tadashi, et al.
Publicado: (2023)

Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study
por: Miyake, Teruki, et al.
Publicado: (2022)

Vaginal and Extra-Vaginal Bacterial Colonization and Risk for Incident Bacterial Vaginosis in a Population of Women Who Have Sex With Men
por: Fredricks, David N, et al.
Publicado: (2020)

Bacterial Pneumonia in Elderly Japanese Populations
por: Miyashita, Naoya, et al.
Publicado: (2018)

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
por: Samukawa, Yoshishige, et al.
Publicado: (2016)

Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice
por: Zhang, Anqi, et al.
Publicado: (2021)

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
por: Bamba, Ryo, et al.
Publicado: (2021)

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
por: Osaka, Naoya, et al.
Publicado: (2022)

Vaginal Microbiomes Associated With Aerobic Vaginitis and Bacterial Vaginosis
por: Kaambo, Evelyn, et al.
Publicado: (2018)

Association between vaginal washing and vaginal bacterial concentrations
por: Sabo, Michelle C., et al.
Publicado: (2019)

Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
por: Sano, Motoaki, et al.
Publicado: (2018)

Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial
por: Ishibashi, Ryoichi, et al.
Publicado: (2020)

Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial
por: Shestakova, Marina, et al.
Publicado: (2023)

Bacterial vaginal infections in diabetic and non-diabetic women
por: Lakshmi, K, et al.
Publicado: (2012)

Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
por: Sasaki, Takashi, et al.
Publicado: (2018)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

The Human Vaginal Bacterial Biota and Bacterial Vaginosis
por: Srinivasan, Sujatha, et al.
Publicado: (2008)

Relationship of Fungal Vaginitis Therapy to Prior Antibiotic Exposure
por: Glover, Douglas D., et al.
Publicado: (2003)

The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections
por: Boahen, Angela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gadmrimf7095qe9tsqr3h9tr1c